U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
119311119311Metabolic Effects of ParicalcitolCompletedHas ResultsChronic Kidney DiseaseDrug: Paricalcitol|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01003275
119312119312Evaluating an Emergency Department Observation Syncope Protocol for Older AdultsCompletedNo Results AvailableSyncopeOther: Emergency Department Observation Protocol|Other: Unstructured, inpatient evaluationhttps://ClinicalTrials.gov/show/NCT01003262
119313119313Dysfunctional Voiding and Lower Urinary Tract Symptoms With BaclofenTerminatedNo Results AvailableOveractive Bladder|Constipation|Lower Urinary Tract SymptomsDrug: Baclofen|Drug: Placebo Comparator: Placebohttps://ClinicalTrials.gov/show/NCT01003249
119314119314Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic NephropathyCompletedNo Results AvailableDiabetic NephropathyDrug: placebo|Drug: Milk Thistle extracthttps://ClinicalTrials.gov/show/NCT01003236
119315119315Phosphate Kinetic ModelingCompletedNo Results AvailableEnd Stage Renal Disease|HyperphosphatemiaOther: Computer algorithm management of hyperphosphatemiahttps://ClinicalTrials.gov/show/NCT01003223
119316119316Homeopathic Ear Drops for Otitis Media StudyCompletedHas ResultsOtitis MediaDrug: Hyland's earache dropshttps://ClinicalTrials.gov/show/NCT01003210
119317119317Novel Preoperative Score Predicting Outcome Following Liver ResectionCompletedNo Results AvailableSerious Complications Following Liver Resectionhttps://ClinicalTrials.gov/show/NCT01003197
119318119318Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesCompletedHas ResultsType 2 Diabetes MellitusDrug: exenatide once weekly|Drug: insulin detemirhttps://ClinicalTrials.gov/show/NCT01003184
119319119319Pharmacokinetics of MCS in Healthy VolunteersNot yet recruitingNo Results AvailableHealthyDrug: MCS-2 soft-gel capsulehttps://ClinicalTrials.gov/show/NCT01003171
119320119320Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.CompletedNo Results AvailableNeoplasms|Metastatic Cancer|Breast CancerDrug: AZD8931|Drug: Paclitaxelhttps://ClinicalTrials.gov/show/NCT01003158
119321119321Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and EldersCompletedNo Results AvailableInfluenzaBiological: Influenza A (H1N1) 2009 monovalent vaccine, inactivatedhttps://ClinicalTrials.gov/show/NCT01003145
119322119322Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following PsychosisCompletedNo Results AvailablePsychosis|Schizophrenia|Bipolar Disorder|Schizo-affective DisorderOther: Acceptance and Commitment Therapyhttps://ClinicalTrials.gov/show/NCT01003132
119323119323Computer-Based Alcohol Use Disorder Recovery SystemCompletedNo Results AvailableAlcohol DependenceBehavioral: Addiction CHESShttps://ClinicalTrials.gov/show/NCT01003119
119324119324Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein OcclusionsCompletedNo Results AvailableRetinal Vein OcclusionDrug: Ranibizumab .5mg|Drug: Ranibizumab .5mg with laser|Drug: Ranibizumab 2.0 mg|Drug: Ranibizumab 2.o dose with laserhttps://ClinicalTrials.gov/show/NCT01003106
119325119325A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit VaccineCompletedNo Results AvailableTuberculosisBiological: 50 microgram antigen (Ag85B + ESAT-6)|Biological: 50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|Biological: 50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1ahttps://ClinicalTrials.gov/show/NCT01003093
119326119326Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized TrialCompletedHas ResultsKnee ArthroplastyDevice: Aquamantys Device|Other: Standard of care treatment for hemostasis during a total knee arthroplasty.https://ClinicalTrials.gov/show/NCT01003080
119327119327Intraperitoneal Mesh-Implementation After LaparotomyActive, not recruitingNo Results AvailableIncisional HerniaDevice: Mesh implementationhttps://ClinicalTrials.gov/show/NCT01003067
119328119328Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNo Results AvailableChronic Myelogenous LeukemiaDrug: Busulfan|Drug: Cyclophosphamide|Drug: Imatinib Mesylate|Procedure: Autologous Stem Cell Transplantationhttps://ClinicalTrials.gov/show/NCT01003054
119329119329The Influence of Hearing Discrete Phonemes in Mother's Voice in the Infant's Natural Environment and With Natural Melody on Developing Phonetic Categories Between 4-10 Months OldNot yet recruitingNo Results AvailableHealthyhttps://ClinicalTrials.gov/show/NCT01003041
119330119330Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled InfusionNot yet recruitingNo Results AvailableAnesthesiaDrug: Remifentanil (Limited) - Target Controlled Infusion system|Drug: Remifentanil (Control) - Target Controlled Infusion systemhttps://ClinicalTrials.gov/show/NCT01003028
119331119331Safety Study of BAY73-4506 in Patients With Hepatocellular CarcinomaCompletedNo Results AvailableCarcinoma, HepatocellularDrug: BAY73-4506https://ClinicalTrials.gov/show/NCT01003015
119332119332Natural History of Levodopa-Induced Dyskinesia (LID)WithdrawnNo Results AvailableParkinson's DiseaseDrug: Levodopa (delivered intravenously)https://ClinicalTrials.gov/show/NCT01003002
119333119333Validation of WatchBP Office Ankle-brachial Index (ABI) FunctionCompletedHas ResultsHypertensionDevice: Doppler Ankle-Brachial Index measurement|Device: WatchBP Office Ankle-Brachial Index measurement.https://ClinicalTrials.gov/show/NCT01002989
119334119334Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe AsthmaWithdrawnNo Results AvailableSevere Allergic Asthmahttps://ClinicalTrials.gov/show/NCT01002976
119335119335A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy VolunteersCompletedNo Results AvailableHealthyDrug: PF-04418948|Drug: PF-04418948|Drug: PF-04418948|Drug: PF-04418948|Drug: PF-04418948|Drug: PF-04418948|Drug: PF-04418948https://ClinicalTrials.gov/show/NCT01002963
119336119336Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic AtrophyCompletedNo Results AvailableDry Age-related Macular Degeneration|Geographic AtrophyDrug: ACU-4429|Drug: Matching placebohttps://ClinicalTrials.gov/show/NCT01002950
119337119337Novel Prognostic Markers in Renal CancerRecruitingNo Results AvailableRenal Cell Carcinomahttps://ClinicalTrials.gov/show/NCT01002937
119338119338Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)Enrolling by invitationNo Results AvailableSolid TumorsDrug: EC145https://ClinicalTrials.gov/show/NCT01002924
119339119339Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)CompletedNo Results AvailableArrythmiasDrug: Cefazolin, Bacitracin, Cefalexin|Drug: Cefazolinhttps://ClinicalTrials.gov/show/NCT01002911
119340119340Ritonavir-boosted Lopinavir MonotherapyCompletedNo Results AvailableHIVDrug: lopinavir/ritonavir soft gel capsulehttps://ClinicalTrials.gov/show/NCT01002898

* Görseller ve İçerik tekif hakkına sahip olabilir